In the context of CAR-NK therapy, humanized mouse nasopharyngeal carcinoma–patient-derived xenografts were used to show the efficacy of the combination therapy involving HSC–derived CAR-NK cells targeting programmed death-ligand 1 (PD-L1) and nivolumab (86). This evidence concerns the gene CD274 and nasopharyngeal carcinoma.